RANBP9

Across TCGA pan-cancer cohorts, RANBP9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RANBP9 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RANBP9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RANBP9 expression acts as an unfavorable survival marker.

BLCA, HNSC, and UCEC are the cancer types where RANBP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.098	0.551	<.001	18	view →
HNSC	OS	Median	All	0.243	0.686	.031	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RANBP9–BLCA (DFS)

Open the BLCA breakdown →